News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Auspex Pharmaceuticals To Present At The Baird 2014 Healthcare Conference

8/28/2014 7:26:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that Pratik Shah, Ph.D., President and Chief Executive Officer, will present at the Baird 2014 Healthcare Conference on Wednesday, September 3, 2014 at 2:55 p.m. EDT at the New York Palace Hotel in New York City.

A live webcast of the presentation will be available through the investor relations section of Auspex Pharmaceutical's website, Following the live webcast, a replay will be available through the same section for 30 days.

About Auspex Pharmaceuticals

Auspex Pharmaceuticals is a late clinical stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Auspex's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome, as well as fibrotic indications, including idiopathic pulmonary fibrosis (IPF) and other orphan conditions. Auspex's lead product candidate, SD-809 (deutetrabenazine), is in a Phase 3 registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Auspex has initiated a Phase 2/3 pivotal clinical trial of SD-809 in tardive dyskinesia and plans to initiate a Phase 3 pivotal clinical study in 2014 of SD-809 in tardive dyskinesia. Further, Auspex has initiated a Phase 1b study in Tourette syndrome. Auspex also is evaluating SD-560 (deuterium-containing form of pirfenidone) in a Phase 1 clinical trial. Auspex has employed its deuterium chemistry approach to optimize other compounds in its portfolio that are at various stages of development. For further information, please visit the company's website

CONTACT: Corporate Communications Contact: Jason Spark at Canale Communications, Inc. 619-849-6005

Auspex Pharmaceuticals logo

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus